Rui G.
- Country
- Portugal
- Department
- Cardiology Department
Research Overview
- Long-term Safety and Tolerability Evaluation of Aficamten (CK-3773274) in Adults with Symptomatic Hypertrophic Cardiomyopathy: An Open-label Extension Study
- Phase 3 Randomized Double-Blind Study of Aficamten Versus Placebo in Adults with Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy
- Efficacy and Safety Evaluation of Sotagliflozin in Patients with Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy
Data & Insights
Has run more than one trial at 45 of 95 partner sites.
Specializations
Cardiac Specialization
This investigator demonstrates dedicated expertise in treating hypertrophic cardiomyopathy (HCM), with particular focus on both obstructive and non-obstructive variants of the condition.
- Non-obstructive HCM management
- Obstructive cardiomyopathy treatment
- Symptomatic cardiac conditions
Their research encompasses innovative therapeutic approaches for managing cardiac muscle disorders.
Therapeutic Innovation
The investigator explores novel therapeutic agents including sotagliflozin and aficamten for cardiac conditions, focusing on symptom improvement and functional outcomes.
- Advanced cardiac therapeutics
- Symptom management strategies
- Exercise capacity assessment
Their work evaluates therapeutic interventions targeting improved quality of life for cardiac patients.
Clinical Assessment
The investigator specializes in evaluating functional limitations and exercise capacity in patients with cardiac conditions.
- Patient health status evaluation
- Functional capacity assessment
- Symptom-based outcomes
Their expertise includes comprehensive assessment of therapeutic efficacy in cardiac patients.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.